CONy 2020 Neuro-immunology Program
Section Heads:
*This program is subject to change
| Saturday, March 28, 2020 | |
| 08:30-10:10 | PANDAS AND CIDP |
| 08:30-09:20 | PANDAS/PANS is a clinically distinct entity and needs early and prompt immunotherapy |
| Capsule: The nosology of pediatric acute neuropsychiatric syndromes remains controversial, and the evidence for immunopathology and in particular autoimmunity driven by Streptococcal infection remains controversial. Is this a distinct disorder and is prompt immunotherapy indicated for treatment? | |
| 08:30-08:40 | Host: Alicja Kalinowska, Poland |
| 08:40-08:55 | Yes: Ronny Wickström, Sweden |
| 08:55-09:10 | No: Ming Lim, UK |
| 09:10-09:20 | Discussion and rebuttals |
| 09:20-10:10 | Treatment of CIDP – immunoglobulins or steroids first? |
| Capsule: Many treatments have been advocated for CIDP, but the best accepted options are intravenous immunoglobulin and corticosteroids. Which treatment is best and should be applied first? | |
| 09:20-09:30 | Host: Joab Chapman, Israel |
| 09:30-09:45 | Immunoglobulins: Marinos Dalakas, USA |
| 09:45-10:00 | Steroids: Eduardo Nobile-Orazio, Italy |
| 10:00-10:10 | Discussion and rebuttals |
| 10:10-10:25 | Coffee Break |
| 10:25-12:05 | NEUROMYELITIS OPTICA SPECTRUM DISORDER |
| 10:25-11:15 | New regulatory-approved medications should be used exclusively for prevention of attacks of NMOSD over (currently used) non-regulatory approved medications |
| Capsule: It is likely that 3 immunomodulatory treatments, a C5 complement inhibitor, an anti-CD19 monoclonal antibody and an inhibitor of IL6 receptor, will all receive regulatory approval for treatment of NMOSD; do these drugs offer sufficient advantages that they should replace currently widely-used immunotherapies that are widely regarded as effective and may be less expensive? | |
| 10:25-10:35 | Host: Brian Weinshenker, USA |
| 10:35-10:50 | Yes: Friedemann Paul, Germany |
| 10:50-11:05 | No: Andrzej Glabinki, Poland |
| 11:05-11:15 | Discussion and rebuttals |
| 11:15-12:05 | NMOSD attacks should be treated with apheresis/plasma exchange at first presentation, either with or without corticosteroids |
| Capsule: Recent retrospective experience suggests that concomitant or first line treatment with plasma exchange may be superior to first line treatment with corticosteroids. Is a change in the standard approach of using corticosteroids first appropriate given the current state of knowledge? | |
| 11:15-11:25 | Host: Bruno Gran, UK |
| 11:25-11:40 | Yes: Ingo Kleiter, Germany |
| 11:40-11:55 | No: M Isabel Leite, UK |
| 11:55-12:05 | Discussion and rebuttals |
| 12:05-13:15 | Industry Symposium |
| 13:15-14:15 | Lunch Break |
| 14:15-15:45 | SECTION TITLE |
| 14:15-14:55 | 2015 International Panel criteria for NMOSD are outdated and should be replaced with a diagnostic classification primarily based on autoantibody status rather than clinical presentation (e.g. AQP4 disease, MOG disease) |
| Capsule: We now know the molecular target of the autoimmune insult in the majority of patients with NMOSD, and we can use a molecular classification based on the target of the antibody in lieu of clinical criteria for diagnosis of what we currently refer to as NMOSD. Some would argue “not so fast.” Are we ready for a molecular classification of NMOSD in 2020? | |
| 14:15-14:25 | Host: Jacek Losy, Poland |
| 14:25-14:35 | Yes: Angela Vincent, UK |
| 14:35-14:45 | No: Ingo Kleiter, Germany |
| 14:45-14:55 | Discussion and rebuttals |
| 14:55-15:45 | Is narcolepsy an autoimmune disorder which should be treated as such? |
| Capsule: summary of debate title | |
| 14:55-15:05 | Host: Friedemann Paul, Germany |
| 15:05-15:20 | Yes: Jack Losy, Poland |
| 15:20-15:35 | No: Angela Vincent, UK |
| 15:35-15:45 | Discussion and rebuttals |
| 15:45-16:00 | Coffee Break |